A new Class of Drugs for BNCT? Borylated derivatives of ferrocenium compounds in animal experiments |
| |
Authors: | L Weissfloch M Wagner T Probst R Senekowitsch-Schmidtke K Tempel M Molls |
| |
Institution: | (1) Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany;(2) Institut für Anorganische Chemie, Johann Wolfgang Goethe-Universität, Marie-Curie-Str. 11, D-60439 Frankfurt am Main, Germany;(3) Institut für Radiochemie, Technische Universität München, Walther-Meißner-Str. 3, 85747 Garching, Germany;(4) Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany |
| |
Abstract: | A new class of drugs, borylated derivatives of ferrocenium compounds, which show a comparatively facile synthesis is investigated on their boron neutron capture accumulation. Investigations focused on the fast and effective testing of 12 ferrocene derivatives with tetracoordinated boron atoms, which should accumulate in rodent tumors. The macroscopic studies on time-dependent boron distributions and boron concentrations in mice were carried out by inductively coupled plasma-atomic emission spectrometry, inductively coupled plasma-mass spectrometry, and quantitative neutron capture radiography. The determination of boron concentrations after injection of 2b showed high boron contents in spleen, liver, kidneys, less in lung and muscle, and poor in integral blood, blood plasma, tumor, and brain. It is interesting to note that 2b penetrates the blood-brain barrier which may be advantageous in the treatment of astrocytomas and glioblastomas. |
| |
Keywords: | boron neutron capture therapy (BNCT) cancer therapy murine tumor models neurological toxicity ferrocene |
本文献已被 SpringerLink 等数据库收录! |
|